CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI–Resistant Metastatic Clear Cell Renal Cell Carcinoma

Se Un Jeong, Hee Sang Hwang, Ja-Min Park, Sun Young Yoon, Su-Jin Shin, Heounjeong Go, Jae-Lyun Lee, Gowun Jeong, Yong Mee Cho

Cancer Research and Treatment. 2023;55(1):231-244. Published online 2022 March 2 DOI: https://doi.org/10.4143/crt.2021.1526

PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI–Resistant Metastatic Clear Cell Renal Cell Carcinoma

Se Un Jeong, Hee Sang Hwang, Ja-Min Park, Sun Young Yoon, Su-Jin Shin, Heounjeong Go, Jae-Lyun Lee, Gowun Jeong, Yong Mee Cho

Cancer Research and Treatment. 2023;55(1):231-244

Link1

Link2 Link3

VEGFR TKI ‘resistance’ or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma

A. Ravaud, L. Digue, N. Trufflandier, D. Smith

Annals of Oncology. 2010;21(2):431-432

Link1 Link2 Link3

Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?

Laurence Albiges, Ronan Flippot, Bernard Escudier

European Urology. 2021;79(6):793-795

Link1 Link2

Upregulation of Pole2 Promotes Clear Cell Renal Cell Carcinoma Progression via AKT/mTOR Pathway and Predicts a Poor Prognosis

Yajuan Su, Changfu Li, Kun Liu, Liangjun Wei, Dechao Li, Wentao Wang, Yongpeng Xu, Hongxin Pan, Lichen Teng

. 2020;

Link1 Link2

PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review

Albert Jang, Patrick L. Sweeney, Pedro C. Barata, Vadim S. Koshkin

Kidney Cancer. 2021;5(1):31-46

Link1

TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma

Xudong Guo, Ruxia Li, Qiulei Bai, Shaobo Jiang, Hanbo Wang

. 2020;

Link1 Link2

Upregulation of ARNTL2 Predicts Poor Survival for Clear Cell Renal Cell Carcinoma and Explores its Associations with PD-L1 and Immune Infiltration

Song Wang, Xueyou Ma, Yufan Ying, Jiazhu Sun, Zitong Yang, Jiangfeng Li, Ke Jin, Xiao Wang, Bo Xie, Xiangyi Zheng, Ben Liu, Liping Xie

. 2021;

Link1 Link2

Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor

Inkeun Park, Jae-Lyun Lee, Jin-Hee Ahn, Dae-Ho Lee, Kyoo-Hyung Lee, Dalsan You, In Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn

Cancer Chemotherapy and Pharmacology. 2015;75(5):1025-1035

Link1

Link2 Link3

Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma

Su-Kang Kong, Byung Soo Kim, Hyangsoon Lim, Hyun Ji Kim, Young-Sik Kim

Laboratory Investigation. 2022;102(4):352-362

Link1

Link2 Link3 Link4 Link5

Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)

B.A. McGregor, A.-K. Lalani, W. Xie, J.A. Steinharter, D.J. Martini, P.V. Nuzzo, N. Martinez Chanza, L.C. Harshman, M.A. Bilen, T.K. Choueiri

Annals of Oncology. 2018;29:viii311

Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.